Table 2 Characteristics associated with serological prescription among EM episodes reported between 2011 and 2020, N = 1684
Prescription of a serological test | |||||
|---|---|---|---|---|---|
n in row (%) | Crude OR [95% CI] | p-value | Adjusted OR [95% CI] | p-value | |
Patients and episodes characteristics | |||||
Age, in years | 0.21 | 0.94 | |||
≤ 15 | 26 (16.6) | 0.70 [0.37–1.32] | 0.83 [0.37–1.87] | ||
]15–35] | 56 (23.1) | 1.06 [0.63–1.79] | 0.94 [0.46–1.89] | ||
]35–50] | 70 (21.7) | Ref. | Ref. | ||
]50–65] | 127 (24.5) | 1.36 [0.88–2.10] | 1.11 [0.63–1.96] | ||
More than 65 | 76 (20.9) | 1.01 [0.63–1.63] | 0.95 [0.51–1.77] | ||
Gender | 0.16 | 0.15 | |||
Female | 192 (23.2) | Ref. | Ref. | ||
Male | 155 (21.1) | 0.80 [0.58–1.09] | 0.74 [0.49–1.11] | ||
Reported tick bite | < 0.001 | < 0.01 | |||
Yes | 196 (19.0) | Ref. | Ref. | ||
No | 108 (27.1) | 2.21 [1.52–3.20] | 1.95 [1.23–3.09] | ||
Erythema migrans size | < 0.001 | < 0.001 | |||
< 5 centimeters | 49 (13.9) | Ref. | Ref. | ||
≥ 5 centimeters | 296 (24.1) | 3.04 [1.94–4.74] | 4.34 [2.33–8.08] | ||
Type of EM | < 0.001 | < 0.01 | |||
Single | 319 (21.0) | Ref. | Ref. | ||
Multiple | 30 (42.2) | 3.73 [1.91–7.29] | 3.82 [1.63–8.92] | ||
Centrifugal growth | 0.32 | 0.42 | |||
Yes | 278 (20.5) | Ref. | Ref. | ||
No | 21 (25.0) | 1.43 [0.71–2.86] | 1.41 [0.61–3.26] | ||
SGPs characteristics | |||||
Age, in years | 0.06 | 0.37 | |||
≤ 40 | 58 (17.7) | Ref. | Ref. | ||
]40–50] | 90 (24.1) | 1.95 [1.02–3.70] | 1.61 [0.77–3.35] | ||
]50–60] | 123 (25.1) | 2.39 [1.26–4.52] | 0.94 [0.43–2.05] | ||
More than 60 | 76 (18.9) | 1.79 [0.90–3.55] | 1.32 [0.56–3.11] | ||
Gender | 0.18 | 0.55 | |||
Female | 111 (22.4) | Ref. | Ref. | ||
Male | 244 (22.0) | 1.45 [0.84–2.52] | 0.83 [0.44–1.56] | ||
Type of practice | 0.09 | 0.72 | |||
Individual | 136 (23.7) | Ref. | Ref. | ||
In groups | 180 (20.7) | 0.60 [0.33–1.08] | 0.89 [0.48–1.66] | ||
Municipality of practice | 0.60 | 0.85 | |||
Rural | 97 (20.9) | Réf. | Réf. | ||
Urban | 258 (22.6) | 1.16 [0.66–2.05] | 1.06 [0.56–2.03] | ||
Regions by incidence rates1,2 | 0.52 | 0.16 | |||
Low incidence region | 139 (27.0) | 1.37 [0.77–2.43] | 1.93 [0.94–3.96] | ||
Moderate incidence region | 74 (23.8) | 1.34 [0.67–2.70] | 1.84 [0.81–4.18] | ||
High incidence region | 141 (18.2) | Ref. | Ref. | ||
Number of cases seen by SGPs on a yearly basis | < 0.001 | < 0.01 | |||
≤ 1 case | 150 (38.5) | 5.42 [2.48–11.84] | 5.28 [1.73–16.11] | ||
]1–5[ | 168 (20.6) | 2.18 [1.00–4.76] | 2.19 [0.77–6.20] | ||
≥ 5 cases | 37 (9.3) | Ref. | Ref. | ||
Year of diagnosis | < 0.001 | < 0.001 | |||
2011–2014 | 141 (41.2) | 4.79 [3.21–7.16] | 4.80 [2.77–8.33] | ||
2015–2019 | 214 (16.9) | Ref. | Ref. | ||